AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24738516
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone and testosterone enanthate injections
Trial: 18422205
Drug: Long-term anti-platelet
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term anti-platelet therapy
Trial: 16316859
Drug: Dozozin‐2 (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dozozin‐2 (test formulation)
Trial: 16316859
Drug: Cardura (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardura (reference formulation)
Trial: 11128850
Drug: CHO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO treatment (glucose 60 g x L(‐1))
Trial: 11128850
Drug: PLA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA treatment (placebo drink)
Trial: 11128850
Drug: RFI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFI treatment (restricted fluid intake with 200 mL placebo)
Trial: 3698655
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg naftidrofuryl daily
Trial: 26751236
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery and intraperitoneal chemotherapy (5-fluorouracil 550 mg/m²/d for 6 days, repeated monthly for 6 months)
Trial: 26751236
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (oxaliplatin and 5-fluorouracil regimen every second week for 6 months)
Trial: 26751236
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery and intraperitoneal chemotherapy
Trial: 25323203
Drug: Narrative Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Exposure Therapy (NET-1)
Trial: 22661123
Drug: Adenosine 25
RxNorm normalized name: adenosine 25 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 25 μg/kg/min
Trial: 22661123
Drug: Adenosine 50
RxNorm normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 50 μg/kg/min
Trial: 22661123
Drug: Adenosine 100
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 100 μg/kg/min
Trial: 22661123
Drug: Adenosine 200
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 200 μg/kg/min
Trial: 10621537
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs for inflamed pterygia
Trial: 9295497
Drug: Food intake
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food intake during intestinal preparation
Trial: 9295497
Drug: Fasting during
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting during intestinal preparation
Trial: 31215460
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (intravenous continuous infusion of regular human insulin at a rate of 0.1 units/kg·h to 0.3 units/kg·h)
Trial: 23911102
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of injectable form of tranexamic acid (500 mg in 5 mL)
Trial: 23911102
Drug: Anterior nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior nasal packing with pledgets coated with tetracycline ointment
Trial: 19356743
Drug: Telemedicine cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine cognitive behavioral therapy (CBT)
Trial: 22706833
Drug: Face-to-face cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive behavioral therapy (CBT)
Trial: 16910866
Drug: 0.4% ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% ketorolac tromethamine ophthalmic solution
Trial: 16910866
Drug: 0.5% ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ketorolac tromethamine ophthalmic solution
Trial: 14962400
Drug: Key-pressing actions
RxNorm normalized name: LEMON OIL, COLD PRESSED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Key-pressing actions producing auditory effects; no specific dosage or duration mentioned
Trial: 9232045
Drug: Intravenous penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous penicillin G sodium, 250,000 U/kg every 24 hours
Trial: 337985
Drug: Oral droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral droperidol
Trial: 8355866
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam plus droperidol
Trial: 29167877
Drug: Ketamine (0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.23 mg/kg infusion over 1 minute followed by 0.58 mg/kg/h infusion over 30 minutes and then 0.29 mg/kg/h infusion over 29 minutes)
Trial: 20103540
Drug: Celiac plexus
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiac plexus block with 25 mL bupivacaine 0.25%
Trial: 18928102
Drug: Paidu Baoshen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paidu Baoshen Pill (PBP) 3 g twice a day
Trial: 18928102
Drug: Oxidative amylase
RxNorm normalized name: amylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxidative amylase aldehyde enveloped capsule 5-10 capsules thrice a day
Trial: 18928102
Drug: Paidu Baoshen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paidu Baoshen Pill (PBP)
Trial: 16386522
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg/day) on days 0 and 4 posttransplant
Trial: 16386522
Drug: Daclizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1 mg/kg per day) on days 0 and 15 posttransplant
Trial: 16386522
Drug: Interleukin-2-receptor blockade
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Interleukin-2-receptor blockade
Trial: 9930597
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (24% PT-IgE at 7 months)
Trial: 9930597
Drug: Whole-cell pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell pertussis vaccine (3% PT-IgE at 7 months)
Trial: 8049448
Drug: Methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1 mg/kg IV for days 1-22, then 0.5 mg/kg for days 22-35)
Trial: 3133251
Drug: Purified follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified follicle-stimulating hormone (pure-FSH)
Trial: 11604193
Drug: Danazol 200
RxNorm normalized name: danazol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol 200 mg vaginal suppositories three times during 2 days before administering misoprostol.
Trial: 11604193
Drug: Placebo suppositories.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories.
Trial: 31907080
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daily lutein supplementation for 12 weeks
Trial: 26755665
Drug: Pharmacist-led telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led telephone consultations (2 consultations, 4-6 weeks apart) plus a written summary and a medicines reminder chart.
Trial: 24866022
Drug: Na-selenite treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na-selenite treatment (1000-μg/2 hours load, followed by 1000-μg/die)
Trial: 24866022
Drug: Na-selenite treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na-selenite treatment
Trial: 16055569
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine continuous wound infusion
Trial: 7574757
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (preoperative hyperthermia, irradiation, 5-fluorouracil suppository)
Trial: 31352906
Drug: Plasma retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma retinol levels (per 10 μg/dl increases)
Trial: 31352906
Drug: Quartile 2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quartile 2-4 retinol levels (≥ 52.3 μg/dl) compared to quartile 1 (< 52.3 μg/dl)
Trial: 31352906
Drug: Plasma retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma retinol levels (per 10 μg/dl increases) in participants with retinol < 68.2 μg/dl
Trial: 31352906
Drug: Plasma retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma retinol levels (per 10 μg/dl increases) in participants with retinol ≥ 68.2 μg/dl
Trial: 29474547
Drug: Substance use
RxNorm normalized name: reSET Substance Use Disorder Therapy Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance use treatment and trauma symptom management
Trial: 26669430
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of Ca (2·4 g Aquamin)
Trial: 26669430
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of Ca with 3 g of scFOS
Trial: 22621166
Drug: G79 (primer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G79 (primer application + heat treatment at 79°C) without aging
Trial: 22621166
Drug: G100 (primer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G100 (primer application + heat treatment at 100°C)
Trial: 22621166
Drug: G45 (primer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G45 (primer application + heat treatment at 45°C)
Trial: 17388962
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day (group B)
Trial: 11605079
Drug: d-amphetamine sulfate
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine sulfate (10 mg and 20 mg)
Trial: 11605079
Drug: bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion hydrochloride (150 mg and 300 mg)
Trial: 4553818
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (AMCA, Cyclokapron), 1 g three times a day for five days
Trial: 31005246
Drug: Standard analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic treatment (arm A)
Trial: 17011409
Drug: Faropenem medoxomil
RxNorm normalized name: Faropenem medoxomil
DrugBank: Faropenem medoxomil (DB05659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faropenem medoxomil 300 mg twice daily for 7 days
Trial: 17011409
Drug: Faropenem medoxomil
RxNorm normalized name: Faropenem medoxomil
DrugBank: Faropenem medoxomil (DB05659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faropenem medoxomil 300 mg twice daily for 10 days
Trial: 17011409
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 250 mg twice daily for 10 days
Trial: 11402108
Drug: IV immunoglobulin
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV immunoglobulin (IVIg) 0.4 g/kg daily for 5 days followed by three single infusions monthly for 3 months
Trial: 3026294
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Hydrochlorothiazide plus Enalapril)
Trial: 24100256
Drug: Remifentanil target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil target-controlled infusion
Trial: 24100256
Drug: Dexmedetomidine single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine single-dose administration (0.5 μg/kg given 10 minutes before the end of surgery)
Trial: 24100256
Drug: Dexmedetomidine single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine single-dose administration
Trial: 25272534
Drug: 2% Diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Diltiazem gel applied twice daily for two weeks
Trial: 14623690
Drug: Long-pulse 532-nm
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-pulse 532-nm Nd:YAG laser treatment
Trial: 10638174
Drug: 0.1% isotretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% isotretinoin gel
Trial: 10621853
Drug: 0.1% isotretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% isotretinoin gel after placebo
Trial: 8961487
Drug: Sequential alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential alternating chemotherapy (Adriamycin/cisplatin and bleomycin/vinblastine; 8.5 +/- 5 cycles)
Trial: 8961487
Drug: Standard PEB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PEB chemotherapy (cisplatinum/etoposide/bleomycin; 5.7 +/- 2.1 cycles)
Trial: 8961487
Drug: Retroperitoneal lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroperitoneal lymph node dissection (RPLND) after chemotherapy
Trial: 1809531
Drug: 4 basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 basic chemicals (imipramine, norephedrine, nicotine, 8-aminoquinoline) applied via a 24-hour patch
Trial: 7073415
Drug: Colestipol hydrochloride
RxNorm normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colestipol hydrochloride (15, 20, and 30 g/day)
Trial: 7073415
Drug: Clofibrate (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate (2.0 g/day)
Trial: 27351320
Drug: Silodosin 8
RxNorm normalized name: silodosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 8 mg daily
Trial: 27351320
Drug: Lactose tablets
RxNorm normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose tablets (Control)
Trial: 22107266
Drug: Preseasonal rush
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preseasonal rush immunotherapy using depigmented polymerized allergenic extract of mixed grass pollen
Trial: 11802108
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg)
Trial: 10197230
Drug: Inhaled lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lignocaine 40 mg
Trial: 10197230
Drug: Inhaled lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lignocaine 160 mg
Trial: 3291558
Drug: Metoprolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (mean dose 197 mg/day)
Trial: 3291558
Drug: Atenolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (mean dose 86 mg/day)
Trial: 3291558
Drug: Propranolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean dose 305 mg/day)
Trial: 30595565
Drug: Ergocalciferol (50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (50,000 IU weekly) with calcitriol (0.25 mg/d) for 3 months
Trial: 27488472
Drug: belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: belimumab 10 mg/kg + standard of care (SoC)
Trial: 27488472
Drug: belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: belimumab 10 mg/kg + steroids only
Trial: 27488472
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + steroids only
Trial: 27488472
Drug: belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: belimumab 10 mg/kg + steroids + AM
Trial: 27488472
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + steroids + AM
Trial: 17932136
Drug: ATP infusion
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP infusion (80 mug (kg body mass)(‐1) min(‐1))
Trial: 17932136
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ATP infusion)
Trial: 9475565
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 10 mg once a day
Trial: 8523629
Drug: Growth hormone,
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone, glutamine, and a modified high-carbohydrate, high-fiber diet
Trial: 30687994
Drug: diacerein 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacerein 100 mg/day
Trial: 27102407
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of workplace environmental dietary modification and educational intervention
Trial: 25715572
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of iontophoresis and magnetic field (20 procedures)
Trial: 21531481
Drug: HiDHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HiDHA supplementation (1000 mg of tuna oil; comprising 252 mg DHA, 60 mg EPA and 10 mg vitamin E)
Trial: 21531481
Drug: Placebo (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1000 mg soybean oil)
Trial: 10030765
Drug: Ropinirole plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole plus L-dopa
Trial: 7573879
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block using 0.125% bupivacaine with adrenaline + rectally administered diclofenac 1 mg.kg‐1
Trial: 2344682
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg orally
Trial: 2040325
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 75 mg daily
Trial: 24709264
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg orally twice daily for 5 days (RESI-VAL)
Trial: 24709264
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (RESI-PLA)
Trial: 24709264
Drug: Vehicle and
RxNorm normalized name: Vehicle and emulsifier patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle and oral placebo (VEH-PLA)
Trial: 22079954
Drug: Daily enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily enteral zinc, selenium, glutamine, and intravenous metoclopramide (n = 149)
Trial: 22079954
Drug: Daily enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily enteral whey protein (n = 144)
Trial: 15178151
Drug: Alpha‐lactalbumin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha‐lactalbumin supplement combined with carbohydrates (AS)
Trial: 11771585
Drug: Ni‐Ti Pow‐R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ni‐Ti Pow‐R 0.04 ISO taper rotary files
Trial: 11771585
Drug: Ni‐Ti ProFile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ni‐Ti ProFile 0.04 ISO taper rotary files
Trial: 10099033
Drug: Delapril 30
RxNorm normalized name: Delapril
DrugBank: Delapril (DB13312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril 30 mg + Indapamide 1.25 mg once daily for 24 weeks
Trial: 2952046
Drug: Foscarnet 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet 0.3% cream
Trial: 24853311
Drug: Adherence counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence counseling intervention based on Lifesteps, an evidence-based HIV treatment adherence intervention; median number of sessions: 10.
Trial: 22330696
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m(2)) and carboplatin (AUC 6) followed by irradiation to the involved field (50.4 Gy pelvis ± 43.5 Gy paraaortic) ± brachytherapy
Trial: 20645945
Drug: Remifentanil 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.5 ng.ml(‐1)
Trial: 20645945
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 ng.ml(‐1) remifentanil)
Trial: 20645945
Drug: Remifentanil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.0 ng.ml(‐1)